According to a new research report “Dry Eye Syndrome Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, dry eye syndrome therapeutics currently exhibits a proliferating pipeline of 50+ therapeutic candidates.

Dry Eye Syndrome Therapeutics Pipeline Insights

Dry eye syndrome, also known as dry eye disease, keratitis sicca and keratoconjunctivitis sicca, is a form of ocular surface and tears disease that results in problems in vision, discomfort and tear film instability, causing potential damage to the ocular surface. It can also overlap with other causes of ocular surface disease such as meibomian gland dysfunction and ocular allergy. The ocular surface consists of seven components including the lacrimal and accessory lacrimal apparatus, the tear film, the nasolacrimal drainage system, the bulbar and tarsal conjunctiva, the eyelids, cranial nerve V and cranial nerve VII. Any abnormalities or deficiencies in one of these ocular surface components may worsen the condition of dry eye syndrome in a patient. Dry eye syndrome is categorized into two types which includes dry eye syndrome associated with Sjögren syndrome and dry eye syndrome unassociated with Sjögren syndrome.

The diagnosis of the diseases can be done using tests such as tear film break-up time and Schirmer test. Eye drops, artificial tears, ointment, and medications such as cyclosporin are some of the treatments that can help reduce the symptoms of the disease. Xiidra (by Shire plc) and Diquas (by Santen Pharmaceutical Co. Ltd.) are some of the marketed drugs for the treatment of dry eye syndrome.

Insights on Pipeline Segments

According to the research, most of the therapeutic drug candidates are being developed for topical administration. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction, and therefore, improves patient compliance.

Positive Clinical Trial Results are Expected to Drive the Dry Eye Syndrome Therapeutics Pipeline

The companies who are involved in developing therapeutics for dry eye syndrome have shown positive clinical results in the various phases of drug development. For instance, HL036, an anti- tumor necrosis factor (TNF) biobetter antibody, is being developed by HanAll BioPharma in collaboration with Harbour BioMed for the treatment of inflammatory diseases. The results from the Phase II clinical trials of the drug candidate, showed statistically significant improvement of the symptoms, in the patients with dry eye syndrome.

Strategic Development Activities Play a Pivot Role in the Growth of Dry Eye Syndrome Therapeutics Pipeline

In September 2017, HanAll BioPharma and Harbour BioMed entered into a collaboration and license agreement to develop, manufacture and commercialize in Greater China (including Hong Kong, Macau and Taiwan) HanAll's two products, the anti-FcRn monoclonal antibody, HL161, for the treatment of pathogenic IgG-mediated autoimmune diseases; and the anti-TNF ophthalmic solution, HL036, for the treatment of dry eye syndrome and other inflammatory diseases.

Browse report overview with detailed TOC on "Dry Eye Syndrome Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/dry-eye-syndrome-therapeutics-pipeline-analysis

Moreover, in September 2017, Redwood Pharma AB contracted the Swiss contract research organization (CRO) CROss Alliance for the management of a clinical Phase II clinical trial of the drug candidate, RP101, in patients with chronic dry eye disease.

TopiVert Pharma Limited, Redwood Pharma AB, HanAll BioPharma, Takeda Pharmaceutical Company Limited, Mitotech SA, Harbour BioMed, and Samjin Pharm Co. Ltd. are some of the key companies involved in the development of dry eye syndrome therapeutics.

Dry Eye Syndrome Therapeutics Pipeline Analysis

• By Phase
• By Molecule Type
• By Route of Administration
• By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of dry eye syndrome. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the dry eye syndrome therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to dry eye syndrome.